PMCB News - Candlesense

PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications

(NASDAQ:PMCB) LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced that it has increased its stake in TNF Pharmaceuticals (Nasdaq: TNF...

What regulatory, adoption and competitive risks are associated with the new accelerator technology, and how might they influence the stocks' price trajectories? What impact could the Light Speed Computing platform’s exposure to cryptocurrency applications have on the valuation and risk profile of both PMCB and TNFA relative to peers? How will PharmaCyte's increased $3 million stake in TNF and the LightSolver licensing deal affect its near‑term earnings and cash flow?

Investments

9 days ago

PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced the closing of its previously announced $7 million financing. As of April 30, 202...

How does PharmaCyte's cash position and financing compare to peers in the biotech sector, and what does it suggest about its ability to fund R&D and potential dilution risk? What specific milestones or timelines does PharmaCyte have for deploying these funds, and how might they impact upcoming earnings or product milestones? How will the $7 million financing and strengthened balance sheet affect PMCB's valuation and price targets?

Financing

22 days ago

PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors

LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”) announced today that it has entered into a securities purchase agreement for a $7.0 million financ...

How does this $7 million capital raise compare to PharmaCyte's recent financing activities and to similar biotech funding rounds in the market? What are the conversion terms and timeline for the preferred stock to become common shares, and how might that impact the share supply? How will the issuance of Series C convertible preferred stock affect the dilution of existing shareholders?

Funding

24 days ago